Home  /  Resource Library  /  Single Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose Escalation Study

Single Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose Escalation Study

Results of a phase I study investigating Mosunetuzumab for treatment of relapsed B-cell lymphomas.